analytica 2022: New instruments for personalized medicine

Mass spectrometry and the like as tools of biomarker analytics

19-May-2022 - From cancer to birth defects to infectious disease: Modern gene and bioanalysis is the key to personalized medicine. Its goal it to increase the success rate of recovery and minimize side effects by examining the illness and the individual characteristics of a patient as precisely as possible. ...

Lab-on-chip systems: From prototype to series production in no time

Globally unique solution saves time and costs

31-Jan-2022 - It is used millions of times a day all over the world: as a portable miniature laboratory, the Corona antigen rapid test is currently clearly demonstrating the potential of lab-on-chip systems. Analysis within a very short time is of immense importance, especially during a pandemic. Ever more of ...

Half a needle in a haystack

New method rapidly detects trace amounts of small molecule compounds

07-Nov-2018 - Russian researchers from Prokhorov General Physics Institute of the Russian Academy of Sciences(GPIRAS) and the Moscow Institute of Physics and Technology(MIPT) have developed the world’s first ultrasensitive method for rapid detection of small molecules. This method detects trace amounts of ...

How reliable is diagnostic testing for Zika?

05-Mar-2018 - Globally, Brazil has been the hardest hit by the current Zika outbreak. Almost all cases of Zika-associated malformations in newborns have been reported from this country. DZIF scientists from the Charité – Universitätsmedizin Berlin have shown that molecular diagnostic tests for the Zika virus ...

PerkinElmer to acquire EUROIMMUN for approximately $1.3 Billion

19-Jun-2017 - PerkinElmer, Inc. announced that it has entered into a definitive agreement to acquireEUROIMMUN Medical Laboratory Diagnostics AG. The agreement provides that PerkinElmer will acquire up to a 100% stake in EUROIMMUN. The total purchase price of the transaction based on all outstanding shares ...

Siemens expand its Walpole, Mass. Laboratory Diagnostic manufacturing facility

Siemens will invest $300M over the next four years

15-Dec-2016 - Siemens Healthineers will invest around $300 million in its Walpole, Mass. laboratory diagnostics manufacturing and research and development facility. "The expansion of the Walpole facility fits into the strategic growth plans for the company and allows us to increase our manufacturing footprint ...

Siemens Healthcare agrees to sell microbiology business to Beckman Coulter

Stronger concentration of Diagnostics Division on core business

17-Jul-2014 - Siemens Healthcare is selling its microbiology business to Beckman Coulter Inc., a wholly owned subsidiary of Danaher Corporation. The activities of the microbiology business include systems for the identification and antibiotic susceptibility testing (ID/AST) of microorganisms. The decision ...

Thermo Fisher Scientific and Immundiagnostik Collaborate To Develop Mass Spectrometry-Based Clinical and Research Tools

18-Oct-2012 - Thermo Fisher Scientific, Inc. and Immundiagnostik AG announced a collaboration to develop novel mass spectrometry-based assays for qualitative and quantitative analysis of proteins and peptides. The goal is development of commercial assays to be widely applicable in research and routine clinical ...

MedMira's Biosensor Division to Receive $3 million from ACOA's Atlantic Innovation Fund

Investment in Maple Biosciences Shall Support Development of Revolutionary Diagnostics

19-Jan-2007 - MedMira Inc. will receive up to $3 million from the Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation Fund. This financial contribution shall enable MedMira's biosensor division, Maple Biosciences, to undertake a $5.4 million project to further develop a revolutionary ...

Bayer to sell diagnostics business to Siemens for EUR 4.2 billion

03-Jul-2006 - The Bayer Group plans to sell the Diagnostics Division of Bayer HealthCare to Siemens AG, Munich, Germany, for EUR 4.2 billion. The divestment was approved by the Bayer Supervisory Board. "This decision is fully in line with our strategy for systematically aligning our health care business. We ...